132 related articles for article (PubMed ID: 6389778)
1. Summary: potential of interleukin-2 for the therapy of cancer.
Herberman RB
J Biol Response Mod; 1984 Oct; 3(5):527-32. PubMed ID: 6389778
[No Abstract] [Full Text] [Related]
2. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
3. Natural killer cells and tumor immunity: 1987.
Hiserodt JC; Herberman RB
Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
[No Abstract] [Full Text] [Related]
4. [The activation of natural killer cells. A new approach to adoptive immunotherapy of tumors].
Schwarz R
Fortschr Med; 1988 Oct; 106(29):579-80. PubMed ID: 3266178
[No Abstract] [Full Text] [Related]
5. Immunotherapy of cancer: the end of the beginning?
Durant JR
N Engl J Med; 1987 Apr; 316(15):939-41. PubMed ID: 3493434
[No Abstract] [Full Text] [Related]
6. Clinical trials with IL-2.
Seipp CA; Simpson C; Rosenberg SA
Oncol Nurs Forum; 1986; 13(6):25-9. PubMed ID: 3540866
[No Abstract] [Full Text] [Related]
7. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
Rosenberg S
J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
[No Abstract] [Full Text] [Related]
8. [Expectations in the clinical application of human-recombinant cytokines. 2) Clinical trials of IL-2].
Ohe Y; Saijo N
Nihon Rinsho; 1988 May; 46(5):1093-8. PubMed ID: 3045365
[No Abstract] [Full Text] [Related]
9. [Cancer therapy with interleukin 2 and activated killer cell--a review].
Jondal M; Ullberg M
Lakartidningen; 1987 Apr; 84(18):1553-7. PubMed ID: 3498104
[No Abstract] [Full Text] [Related]
10. Interleukin-2 and killer T cells.
Sticklin LA
Am J Nurs; 1987 Apr; 87(4):468-9. PubMed ID: 3494403
[No Abstract] [Full Text] [Related]
11. [Adoptive immunotherapy: a new therapeutic approach to cancer based on interleukin 2].
Sculier JP; Bron D; Delforge A; Stryckmans P; Klastersky J
Rev Med Brux; 1987 Mar; 8(3):133-9. PubMed ID: 3495843
[No Abstract] [Full Text] [Related]
12. Status and potential of interleukin-2 for the treatment of neoplastic disease.
Sondel PM; Hank JA; Kohler PC
Oncology (Williston Park); 1987 Aug; 1(6):41-9. PubMed ID: 3079485
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].
Osanto S; Brand A; van Rood JJ; Cleton FJ
Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758
[No Abstract] [Full Text] [Related]
14. Implementation of an RIL-2/LAK cell clinical trial: a nursing perspective.
Corey BS; Collins JL
Oncol Nurs Forum; 1986; 13(6):31-6. PubMed ID: 3540867
[No Abstract] [Full Text] [Related]
15. [Interleukin 2, killer cells and cancer].
Timonen T
Duodecim; 1988; 104(9):685-9. PubMed ID: 3049038
[No Abstract] [Full Text] [Related]
16. Immunotherapy of cancer using interleukin 2: current status and future prospects.
Rosenberg SA
Immunol Today; 1988 Feb; 9(2):58-62. PubMed ID: 3076761
[No Abstract] [Full Text] [Related]
17. Lymphokine activated killer cells research in China.
Ba DN
Proc Chin Acad Med Sci Peking Union Med Coll; 1988; 3(3):170-4. PubMed ID: 3064089
[No Abstract] [Full Text] [Related]
18. Identification and activation of tumor-reactive cells for adoptive immunotherapy.
Triozzi PL
Stem Cells; 1993 May; 11(3):204-11. PubMed ID: 8318907
[TBL] [Abstract][Full Text] [Related]
19. The dual effects of interleukin-18 in tumor progression.
Park S; Cheon S; Cho D
Cell Mol Immunol; 2007 Oct; 4(5):329-35. PubMed ID: 17976312
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
